Proteintech, best known for its sprawling antibody catalog, is taking a sharper swing at AI-powered life sciences. The company today announced the launch of Able AI, a new digital tool designed to cut through the noise of antibody selection and speed up research workflows.
If you’ve ever sifted through hundreds of antibody options—each with technical caveats and variable data quality—you’ll appreciate the appeal. Able AI doesn’t just spit out a product list; it draws on Proteintech’s data and testing protocols to surface the most relevant antibodies for a given research purpose. It even guides scientists on product-specific testing procedures, shaving hours (or even days) off the planning phase.
This move follows Proteintech’s earlier rollout of 3D epitope mapping, which combined experimental data and AI modeling to give researchers a clearer look at antibody binding sites. That innovation reduced the trial-and-error common in lab design. With Able, Proteintech is doubling down on the same theme: letting AI shoulder the grunt work so scientists can focus on discovery.
The launch highlights a growing trend: AI isn’t just driving drug discovery or diagnostics—it’s increasingly embedded in the research tools that power everyday bench science. Proteintech’s play also positions it against other reagent giants like Abcam and Thermo Fisher, which have been investing heavily in data-driven platforms to help researchers make smarter choices in crowded product ecosystems.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
